Full Press Release Details
Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results
Company provides initial outlook for Q1 and fiscal year 2026, forecasting a return to revenue growth by year's end
PROVO, Utah - Feb. 12, 2026 - Nu Skin
Enterprises Inc. (NYSE: NUS) today announced fourth quarter and full-year 2025 revenue and earnings within guidance with more than 50% growth in earnings for 2025.
Q4 2025 vs. Prior-year Quarter
| Revenue | $370.3 million; (16.9)% or (10.4)% excluding Mavely 2024 revenue (0.2)% FX impact or $(0.8) million | ||
| Earnings Per Share (EPS) | $0.29 compared to $(0.73) or $0.38 excluding restructuring and other charges | ||
| Customers | 748,796; (10)% | ||
| Paid Affiliates | 129,311; (11)% | ||
| Sales Leaders | 30,045; (19)% |
| Revenue: | $1.49 billion; (14.3)% or (10.7%) excluding Mavely 2024 revenue (0.8)% FX impact or $(13.4) million | ||
| Earnings Per Share (EPS): | $3.18 or $1.27 excluding Mavely gain and other charges compared to $(2.95) or $0.84 excluding restructuring and other charges |
"We are pleased to achieve fourth quarter results within our guidance range for both revenue and earnings per share," said Ryan Napierski, Nu
Skin president and CEO. "This past year was a pivotal year as we furthered our transformation toward becoming the world's leading intelligent beauty and wellness platform and laid the groundwork for our 2026 growth initiatives. Looking ahead, we
continue to build sales leader alignment in the first half of the year around the global launch of Prysm iO, positioning us for a return to year-over-year revenue growth by year's end.
"We are now placing Prysm iO intelligent wellness devices into the hands of sales leaders around the world ahead of our consumer launch in the
second half of the year. More than 20,000 devices are already in the hands of our sales leaders generating more than 700,000 scans. As we gain greater adoption and more individuals are scanning and receiving their personalized product
recommendations, we anticipate this will drive growth in subscriptions leading to greater customer lifetime value. We have also begun pre-market activities in India, setting the operational foundation and infrastructure ahead of a full market
opening anticipated in the back half of the year. Overall, we are encouraged by the progress we are making and believe these two initiatives give us the greatest opportunity for sustainable, long-term growth and increased shareholder value."
Q4 2025 Year-over-year Operating Results
| Revenue | $370.3 million compared to $445.6 million or $413.3 million excluding Mavely 2024 revenue (0.2)% FX impact or $(0.8) million | ||
| Gross Margin | 70.7% compared to 62.7% or 71.4% excluding inventory write-off Nu Skin business was 77.6% compared to 67.5% or 76.6% excluding inventory write-off | ||
| Selling Expenses | 35.5% compared to 37.1% Nu Skin business was 40.8% compared to 40.3% | ||
| G&A Expenses | 29.0% compared to 27.1% | ||
| Operating Margin | 6.3% compared to (11.9)% or 7.7% excluding restructuring and other charges | ||
| Interest Expense | $4.0 million compared to $5.9 million | ||
| Other Income (Expense) | $(1.1) million compared to $1.1 million | ||
| Income Tax Rate | 20.3% compared to 37.5% or 36.6% excluding restructuring and other charges | ||
| EPS | $0.29 compared to $(0.73) or $0.38 excluding restructuring and other charges |
| Dividend Payments | $2.9 million | ||
| Stock Repurchases | $10.0 million $142.3 million remaining in authorization |
Q1 and Full-year 2026 Outlook
| Q1 2026 Revenue | $320 to $340 million; (12)% to (7)% Approximately (1)% FX impact | ||
| Q1 2026 EPS | $0.10 to $0.20 | ||
| 2026 Revenue | $1.35 to $1.50 billion; (9)% to 1% Approximately (1)% FX impact | ||
| 2026 EPS | $0.80 to $1.20 |
"We are pleased with how we performed this year, growing earnings by more than 50% due to effective margin improvement and cost optimization
amidst top-line pressures," said James D. Thomas, chief financial officer. "As we look to return to year-over-year growth by year's end, our annual revenue guidance is $1.35 to $1.50 billion, with an approximate 1% foreign currency headwind. We
anticipate EPS of $0.80 to $1.20 with a forecasted tax rate of 35%. For the first quarter, which is typically our lowest quarter due to seasonality of our business, we project revenue of $320 to $340 million. This assumes a negative foreign
currency impact of approximately 1%. We project earnings per share of $0.10 to $0.20."
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the
webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through Feb. 26, 2026.
About Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc. (NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly
50 markets worldwide. Backed by more than 40 years of scientific research, the company's products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device
systems and trusted brands in personal care and wellness products. Rhyz is the strategic investment arm of Nu Skin Enterprises, formed in 2018 consisting of synergistic consumer, technology and manufacturing companies focused on innovation within
the beauty, wellness and lifestyle categories.
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the
company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of
management's expectations regarding the company's performance, growth, and growth opportunities and initiatives, shareholder value, transformation, the Prysm launch and its potential benefits to the business, and new market expansion and its
timing; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying
any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "become," "continue," "project," "outlook," "guidance," "will," "would," "could," "may," "might," the negative of these
words and other similar words.
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ
materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated
risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided, and the company assumes no
duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
Non-GAAP Financial Measures:
Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by
translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period's revenue. The company believes that constant-currency revenue
change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company's revenue from period to period.
Earnings per share, gross margin, operating margin and income tax rate, each excluding inventory write-off charges, restructuring and impairment
expense, the gain from the Mavely sale, unrealized investment loss, and/or other charges, as well as revenue growth rate excluding Mavely 2024 revenue, also are non-GAAP financial measures.
The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these
items facilitates period-to-period comparisons of the company's performance. Please see the reconciliations of these items to our earnings per share, gross margin, operating margin, income tax rate and revenue growth rate calculated under GAAP,
The following table sets forth revenue for the three-month periods ended December 31, 2025, and 2024 for each of our reportable segments (U.S. dollars in thousands):
| Three Months Ended December 31, | Constant-Currency | |||||||||||||||
| 2025 | 2024 | Change | Change | |||||||||||||
| Nu Skin | ||||||||||||||||
| Americas | $ | 76,977 | $ | 85,356 | (9.8 | )% | (4.5 | )% | ||||||||
| Southeast Asia/Pacific | 50,210 | 64,925 | (22.7 | )% | (22.9 | )% | ||||||||||
| Mainland China | 52,035 | 56,438 | (7.8 | )% | (9.0 | )% | ||||||||||
| Japan | 42,504 | 47,512 | (10.5 | )% | (9.5 | )% | ||||||||||
| Europe & Africa | 41,800 | 42,600 | (1.9 | )% | (10.2 | )% | ||||||||||
| South Korea | 28,431 | 33,423 | (14.9 | )% | (11.8 | )% | ||||||||||
| Hong Kong/ Taiwan | 29,605 | 32,549 | (9.0 | )% | (11.6 | )% | ||||||||||
| Other | 239 | (354 | ) | 167.5 | % | 171.1 | % | |||||||||
| Total Nu Skin | 321,801 | 362,449 | (11.2 | )% | (11.0 | )% | ||||||||||
| Rhyz | ||||||||||||||||
| Manufacturing | 42,451 | 47,882 | (11.3 | )% | (11.3 | )% | ||||||||||
| Rhyz Other | 6,068 | 35,221 | (82.8 | )% | (82.8 | )% | ||||||||||
| Total Rhyz | 48,519 | 83,103 | (41.6 | )% | (41.6 | )% | ||||||||||
| Total | $ | 370,320 | $ | 445,552 | (16.9 | )% | (16.7 | )% |
The following table sets forth revenue for the years ended December 31, 2025, and 2024 for each of our reportable segments (U.S. dollars in thousands):
| Year Ended December 31, | Constant-Currency | |||||||||||||||
| 2025 | 2024 | Change | Change | |||||||||||||
| Nu Skin | ||||||||||||||||
| Americas | $ | 282,975 | $ | 322,516 | (12.3 | )% | (6.2 | )% | ||||||||
| Southeast Asia/Pacific | 209,802 | 244,846 | (14.3 | )% | (14.6 | )% | ||||||||||
| Mainland China | 195,553 | 235,235 | (16.9 | )% | (16.9 | )% | ||||||||||
| Japan | 174,364 | 181,557 | (4.0 | )% | (5.1 | )% | ||||||||||
| Europe & Africa | 150,151 | 164,164 | (8.5 | )% | (12.6 | )% | ||||||||||
| South Korea | 130,216 | 163,706 | (20.5 | )% | (17.1 | )% | ||||||||||
| Hong Kong/ Taiwan | 117,378 | 130,610 | (10.1 | )% | (11.9 | )% | ||||||||||
| Other | 1,138 | 2,832 | (59.8 | )% | (48.5 | )% | ||||||||||
| Total Nu Skin | 1,261,577 | 1,445,466 | (12.7 | )% | (11.8 | )% | ||||||||||
| Rhyz | ||||||||||||||||
| Manufacturing | 205,788 | 201,430 | 2.2 | % | 2.2 | % | ||||||||||
| Rhyz Other | 17,794 | 85,188 | (79.1 | )% | (79.1 | )% | ||||||||||
| Total Rhyz | 223,582 | 286,618 | (22.0 | )% | (22.0 | )% | ||||||||||
| Total | $ | 1,485,159 | $ | 1,732,084 | (14.3 | )% | (13.5 | )% |
The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month
periods ended December 31, 2025, and 2024:
| Three Months Ended December 31, | ||||||||||||
| 2025 | 2024 | Change | ||||||||||
| Customers | ||||||||||||
| Americas | 225,527 | 227,556 | (1 | )% | ||||||||
| Southeast Asia/Pacific | 74,300 | 82,956 | (10 | )% | ||||||||
| Mainland China | 118,523 | 150,731 | (21 | )% | ||||||||
| Japan | 104,439 | 110,069 | (5 | )% | ||||||||
| Europe & Africa | 127,910 | 133,306 | (4 | )% | ||||||||
| South Korea | 58,880 | 81,301 | (28 | )% | ||||||||
| Hong Kong/Taiwan | 39,217 | 46,053 | (15 | )% | ||||||||
| Total | 748,796 | 831,972 | (10 | )% | ||||||||
| Paid Affiliates | ||||||||||||
| Americas | 28,900 | 28,361 | 2 | % | ||||||||
| Southeast Asia/Pacific | 20,260 | 26,310 | (23 | )% | ||||||||
| Mainland China | 18,922 | 22,125 | (14 | )% | ||||||||
| Japan | 20,126 | 22,318 | (10 | )% | ||||||||
| Europe & Africa | 14,918 | 16,860 | (12 | )% | ||||||||
| South Korea | 16,341 | 17,939 | (9 | )% | ||||||||
| Hong Kong/Taiwan | 9,844 | 10,961 | (10 | )% | ||||||||
| Total | 129,311 | 144,874 | (11 | )% | ||||||||
| Sales Leaders | ||||||||||||
| Americas | 6,016 | 6,778 | (11 | )% | ||||||||
| Southeast Asia/Pacific | 4,272 | 5,288 | (19 | )% | ||||||||
| Mainland China | 6,065 | 8,969 | (32 | )% | ||||||||
| Japan | 6,259 | 6,780 | (8 | )% | ||||||||
| Europe & Africa | 2,722 | 3,343 | (19 | )% | ||||||||
| South Korea | 2,547 | 3,343 | (24 | )% | ||||||||
| Hong Kong/Taiwan | 2,164 | 2,411 | (10 | )% | ||||||||
| Total | 30,045 | 36,912 | (19 | )% |
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ | 370,320 | $ | 445,552 | $ | 1,485,159 | $ | 1,732,084 | ||||||||
| Cost of sales | 108,339 | 166,405 | 453,761 | 550,233 | ||||||||||||
| Gross profit | 261,981 | 279,147 | 1,031,398 | 1,181,851 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling expenses | 131,342 | 165,422 | 508,380 | 652,039 | ||||||||||||
| General and administrative expenses | 107,395 | 120,930 | 432,141 | 479,037 | ||||||||||||
| Restructuring and impairment expenses | - | 45,876 | 25,114 | 202,360 | ||||||||||||
| Total operating expenses | 238,737 | 332,228 | 965,635 | 1,333,436 | ||||||||||||
| Operating income (loss) | 23,244 | (53,081 | ) | 65,763 | (151,585 | ) | ||||||||||
| Interest expense | 3,994 | 5,864 | 13,948 | 26,409 | ||||||||||||
| Gain on sale | - | - | 176,162 | - | ||||||||||||
| Other income (expense), net | (1,059 | ) | 1,143 | (31,780 | ) | 2,943 | ||||||||||
| Income (loss) before provision for income taxes | 18,191 | (57,802 | ) | 196,197 | (175,051 | ) | ||||||||||
| Provision (benefit) for income taxes | 3,700 | (21,697 | ) | 35,993 | (28,457 | ) | ||||||||||
| Net income (loss) | $ | 14,491 | $ | (36,105 | ) | $ | 160,204 | $ | (146,594 | ) | ||||||
| Net income (loss) per share: | ||||||||||||||||
| Basic | $ | 0.30 | $ | (0.73 | ) | $ | 3.25 | $ | (2.95 | ) | ||||||
| Diluted | $ | 0.29 | $ | (0.73 | ) | $ | 3.18 | $ | (2.95 | ) | ||||||
| Weighted-average common shares outstanding (000s): | ||||||||||||||||
| Basic | 48,581 | 49,712 | 49,293 | 49,662 | ||||||||||||
| Diluted | 49,912 | 49,712 | 50,301 | 49,662 |
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 238,630 | $ | 186,883 | ||||
| Current investments | 1,211 | 11,111 | ||||||
| Accounts receivable, net | 39,544 | 50,784 | ||||||
| Inventories, net | 178,643 | 190,242 | ||||||
| Prepaid expenses and other | 89,670 | 72,643 | ||||||
| Current assets held for sale | - | 26,936 | ||||||
| Total current assets | 547,698 | 538,599 | ||||||
| Property and equipment, net | 377,168 | 379,595 | ||||||
| Operating lease right-of-use assets | 74,021 | 72,605 | ||||||
| Goodwill | 83,625 | 83,625 | ||||||
| Other intangible assets, net | 42,614 | 74,278 | ||||||
| Other assets | 280,187 | 298,008 | ||||||
| Long-term assets held for sale | - | 22,204 | ||||||
| Total assets | $ | 1,405,313 | $ | 1,468,914 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 26,183 | $ | 34,880 | ||||
| Accrued expenses | 217,551 | 217,808 | ||||||
| Current portion of long-term debt | 20,000 | 30,000 | ||||||
| Current liabilities held for sale | - | 13,919 | ||||||
| Total current liabilities | 263,734 | 296,607 | ||||||
| Operating lease liabilities | 57,640 | 58,439 | ||||||
| Long-term debt | 204,187 | 363,613 | ||||||
| Other liabilities | 74,512 | 97,475 | ||||||
| Long-term liabilities held for sale | - | 1,325 | ||||||
| Total liabilities | 600,073 | 817,459 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity | ||||||||
| Class A common stock - 500 million shares authorized, $0.001 par value, 90.6 million shares issued | 91 | 91 | ||||||
| Additional paid-in capital | 635,994 | 627,787 | ||||||
| Treasury stock, at cost - 42.4 million and 40.8 million shares | (1,575,059 | ) | (1,563,614 | ) | ||||
| Accumulated other comprehensive loss | (116,105 | ) | (124,758 | ) | ||||
| Retained earnings | 1,860,319 | 1,711,949 | ||||||
| Total stockholders' equity | 805,240 | 651,455 | ||||||
| Total liabilities and stockholders' equity | $ | 1,405,313 | $ | 1,468,914 |
NU SKIN ENTERPRISES, INC.
Reconciliation of Revenue Growth Rates Excluding Mavely to GAAP Revenue Growth Rates
| Fourth Quarter | Full Year | |||||||
| 2024 Revenue | $ | 445,552 | $ | 1,732,084 | ||||
| Less: Mavely 2024 Revenue | 32,252 | 69,620 | ||||||
| Adjusted 2024 Revenue | $ | 413,300 | $ | 1,662,464 | ||||
| 2025 Revenue | $ | 370,320 | $ | 1,485,159 | ||||
| Revenue Growth Rate | (16.9 | )% | (14.3 | )% | ||||
| Revenue Growth Rate, excluding Mavely | (10.4 | )% | (10.7 | )% |
NU SKIN ENTERPRISES, INC.
Reconciliation of Gross Margin Excluding Impact of Inventory Write-off to GAAP Gross Margin
| Three months ended December 31, | Year ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Gross Profit | $ | 261,981 | $ | 279,147 | $ | 1,031,398 | $ | 1,181,851 | ||||||||
| Impact of inventory write-off | - | 38,765 | - | 38,765 | ||||||||||||
| Adjusted Gross Profit | $ | 261,981 | $ | 317,912 | $ | 1,031,398 | $ | 1,220,616 | ||||||||
| Gross Margin | 70.7 | % | 62.7 | % | 69.4 | % | 68.2 | % | ||||||||
| Gross Margin, excluding inventory write-off impact | 70.7 | % | 71.4 | % | 69.4 | % | 70.5 | % | ||||||||
| Revenue | $ | 370,320 | $ | 445,552 | $ | 1,485,159 | $ | 1,732,084 |
NU SKIN ENTERPRISES, INC.
Reconciliation of Core Nu Skin Business Gross Margin Excluding Impact of Inventory Write-off to GAAP Gross Margin
| Three months ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Gross Profit | $ | 249,869 | $ | 244,754 | ||||
| Impact of inventory write-off | - | 32,704 | ||||||
| Adjusted Gross Profit | $ | 249,869 | $ | 277,458 | ||||
| Gross Margin | 77.6 | % | 67.5 | % | ||||
| Gross Margin, excluding inventory write-off impact | 77.6 | % | 76.6 | % | ||||
| Revenue | $ | 321,801 | $ | 362,449 |
NU SKIN ENTERPRISES, INC.
Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin
| Three months ended December 31, | Year ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating (loss) income | $ | 23,244 | $ | (53,081 | ) | $ | 65,763 | $ | (151,585 | ) | ||||||
| Impact of inventory write-off | - | 38,765 | - | 38,765 | ||||||||||||
| Impact of other charges (1) | - | 2,940 | 7,966 | 2,940 | ||||||||||||
| Impact of restructuring and impairment | - | 45,876 | 25,114 | 202,360 | ||||||||||||
| Adjusted operating income | $ | 23,244 | $ | 34,500 | $ | 98,843 | $ | 92,480 | ||||||||
| Operating margin | 6.3 | % | (11.9 | )% | 4.4 | % | (8.8 | )% | ||||||||
| Operating margin, excluding certain charges | 6.3 | % | 7.7 | % | 6.7 | % | 5.3 | % | ||||||||
| Operating margin growth | 152.9 | % | 150.0 | % | ||||||||||||
| Operating margin growth (decline), excluding certain charges | (18.2 | )% | 26.4 | % | ||||||||||||
| Revenue | $ | 370,320 | $ | 445,552 | $ | 1,485,159 | $ | 1,732,084 |
(1) Other charges consist of expenses incurred during the first quarter of 2025 in connection with the Mavely sale, including $2.7 million of
transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units. Other charges for the fourth quarter and full year 2024 consist of transaction-related expenses
incurred related to the sale of Mavely.
NU SKIN ENTERPRISES, INC.
Reconciliation of Effective Tax Rate Excluding Impact of Mavely Gain and Certain Charges to GAAP Effective Tax Rate
| Three months ended December 31, | Year ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Provision (benefit) for income taxes | $ | 3,700 | $ | (21,697 | ) | $ | 35,993 | $ | (28,457 | ) | ||||||
| Impact of inventory write-off on provision for income taxes | - | 14,643 | 14,643 | |||||||||||||
| Impact of other charges on provision for income taxes | - | 632 | 725 | 632 | ||||||||||||
| Impact of restructuring and impairment on provision for income taxes | - | 17,329 | 5,433 | 40,399 | ||||||||||||
| Impact of gain on Mavely sale on provision for income taxes | - | - | (31,104 | ) | - | |||||||||||
| Impact of gain on unrealized investment loss on provision for income taxes | - | - | 6,074 | - | ||||||||||||
| Provision for income taxes, excluding impact of certain charges | $ | 3,700 | $ | 10,907 | $ | 17,121 | $ | 27,217 | ||||||||
| Income (loss) before provision for income taxes | 18,191 | (57,802 | ) | 196,197 | (175,051 | ) | ||||||||||
| Impact of inventory-write off | - | 38,765 | - | 38,765 | ||||||||||||
| Impact of other charges (1) | - | 2,940 | 7,966 | 2,940 | ||||||||||||
| Impact of restructuring and impairment expense: | - | 45,876 | 25,114 | 202,360 | ||||||||||||
| Impact of gain on Mavely sale | - | - | (176,162 | ) | - | |||||||||||
| Impact of unrealized investment loss | - | - | 28,077 | - | ||||||||||||
| Income before provision for income taxes, excluding impact certain charges | $ | 18,191 | $ | 29,779 | $ | 81,192 | $ | 69,014 | ||||||||
| Effective tax rate | 20.3 | % | 37.5 | % | 18.3 | % | 16.3 | % | ||||||||
| Effective tax rate, excluding impact of certain charges | 20.3 | % | 36.6 | % | 21.1 | % | 39.4 | % |
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Mavely Gain and Certain Charges to GAAP Earnings Per Share
(in thousands, except for per share amounts)
| Three months ended December 31, | Year ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net income (loss) | $ | 14,491 | $ | (36,105 | ) | $ | 160,204 | $ | (146,594 | ) | ||||||
| Impact of inventory write-off | ||||||||||||||||
| Inventory write-off | - | 38,765 | - | 38,765 | ||||||||||||
| Tax impact | - | (14,643 | ) | - | (14,643 | ) | ||||||||||
| Impact of other charges | ||||||||||||||||
| Other charges (1) | - | 2,940 | 7,966 | 2,940 | ||||||||||||
| Tax impact | - | (632 | ) | (725 | ) | (632 | ) | |||||||||
| Impact of restructuring and impairment expense: | ||||||||||||||||
| Restructuring and impairment | - | 45,876 | 25,114 | 202,360 | ||||||||||||
| Tax impact | - | (17,329 | ) | (5,433 | ) | (40,399 | ) | |||||||||
| Impact of Mavely sale | ||||||||||||||||
| Gain on Mavely sale | - | - | (176,162 | ) | - | |||||||||||
| Tax impact | - | - | 31,104 | - | ||||||||||||
| Impact of unrealized investment loss | ||||||||||||||||
| Unrealized investment loss | - | - | 28,077 | - | ||||||||||||
| Tax impact | - | - | (6,074 | ) | - | |||||||||||
| Adjusted net income | $ | 14,491 | $ | 18,872 | $ | 64,071 | $ | 41,797 | ||||||||
| Diluted earnings per share | $ | 0.29 | $ | (0.73 | ) | $ | 3.18 | $ | (2.95 | ) | ||||||
| Diluted earnings per share, excluding impact of certain charges | $ | 0.29 | $ | 0.38 | $ | 1.27 | $ | 0.84 | ||||||||
| Diluted earnings per share growth | 139.7 | % | 207.8 | % | ||||||||||||
| Diluted earnings per share growth (decline), excluding impact of certain charges | (23.7 | )% | 51.2 | % | ||||||||||||
| Weighted-average common shares outstanding (000) | 49,912 | 49,712 | 50,301 | 49,662 |
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577